Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 18-27

  Yang, J Q ^a,b   Kim, P J ^a   Halder, R C ^a   Singh, R R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

Author keywords

Autoimmunity; Rodent; Systemic lupus erythematosus; T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INVARIANT NATURAL KILLER T CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION;

ANIMALS; ANTIGENS, CD1; CELLS, CULTURED; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COOPERATION; LYMPHOCYTE COUNT; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; NATURAL KILLER T-CELLS; PRODROMAL SYMPTOMS;

EID: 84878780371     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12079     Document Type: Article

References (46)

1. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11:197-206.
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
3. Burdin N, Kronenberg M. CD1-mediated immune responses to glycolipids. Curr Opin Immunol 1999; 11:326-331.
4. Nieda M, Okai M, Tazbirkova A etal. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103:383-389.
5. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23:877-900.
6. Yang JQ, Singh AK, Wilson MT etal. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003; 171:2142-2153.
7. Wen X, Yang JQ, Kim PJ, Singh RR. Homeostatic regulation of marginal zone B cells by invariant natural killer T cells. PLoS ONE 2011; 6:e26536.
8. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009; 9:4-14.
9. Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011; 53:263-270.
10. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 2006; 34:49-66.
11. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44:1127-1138.
12. van der Vliet HJ, von Blomberg BM, Nishi N etal. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100:144-148.
13. Cho YN, Kee SJ, Lee SJ etal. Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. Rheumatology (Oxf) 2011; 50:1054-1063.
14. Oishi Y, Sumida T, Sakamoto A etal. Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001; 28:275-283.
15. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012; 36:477-490.
16. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. Arthritis Rheum 2007; 56:303-310.
17. Wither J, Cai YC, Lim S etal. Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Res Ther 2008; 10:R108.
18. Yang JQ, Wen X, Liu H etal. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007; 56:1219-1233.
19. Yang JQ, Chun T, Liu H etal. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004; 34:1723-1732.
20. Sireci G, Russo D, Dieli F etal. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 2007; 37:425-433.
21. Yang JQ, Kim PJ, Singh RR. Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus. J Clin Immunol 2012; 32:106-113.
22. Singh AK, Yang JQ, Parekh VV etal. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 2005; 35:1143-1154.
23. Jacinto J, Kim PJ, Singh RR. Disparate effects of depletion of CD1d-reactive T cells during early versus late stages of disease in a genetically susceptible model of lupus. Lupus 2012; 21:485-490.
24. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003; 171:4439-4446.
25. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003; 112:1211-1222.
26. 1 mice. J Immunol 2005; 175:763-770.
27. Van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5:31-42.
28. Singh N, Hong S, Scherer DC etal. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163:2373-2377.
29. Carnaud C, Lee D, Donnars O etal. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163:4647-4650.
30. Wilson MT, Johansson C, Olivares-Villagomez D etal. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100:10913-10918.
31. Esteban LM, Tsoutsman T, Jordan MA etal. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol 2003; 171:2873-2878.
32. Singh RR, Saxena V, Zang S etal. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003; 170:4818-4825.
33. Singh AK, Wilson MT, Hong S etal. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:1801-1811.
34. Smith DL, Dong X, Du S, Oh M, Singh RR, Voskuhl RR. A female preponderance for chemically induced lupus in SJL/J mice. Clin Immunol 2007; 122:101-107.
35. Hahn BH, Singh RR. Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Philadelphia, PA: Lippincott, Williams and Wilkins, 2007:299-355.
36. Tsukamoto K, Ohtsuji M, Shiroiwa W etal. Aberrant genetic control of invariant TCR-bearing NKT cell function in New Zealand mouse strains: possible involvement in systemic lupus erythematosus pathogenesis. J Immunol 2008; 180:4530-4539.
37. Yang JQ, Wen X, Kim PJ, Singh RR. Invariant NKT cells inhibit autoreactive B cells in a contact- and CD1d-dependent manner. J Immunol 2011; 186:1512-1520.
38. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010; 207:943-952.
39. Crowe NY, Uldrich AP, Kyparissoudis K etal. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171:4020-4027.
40. Parekh VV, Wilson MT, Olivares-Villagomez D etal. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115:2572-2583.
41. Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J. Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 2011; 41:3312-3322.
42. Bontkes HJ, Moreno M, Hangalapura B etal. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol 2010; 136:364-374.
43. Thapa P, Zhang G, Xia C etal. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009; 27:3484-3488.
44. Parekh VV, Lalani S, Kim S etal. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182:2816-2826.
45. Chang WS, Kim JY, Kim YJ etal. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008; 181:6707-6710.
46. Kojo S, Elly C, Harada Y, Langdon WY, Kronenberg M, Liu YC. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proc Natl Acad Sci USA 2009; 106:17847-17851.